Latest news with #Camlin
Economic Times
15 hours ago
- Business
- Economic Times
Camlin Fine Sciences sees 51% surge in shares amid anti-dumping duties on Chinese Vanillin
ET Intelligence Group: Shares of Camlin Fine Sciences, a manufacturer and exporter of specialty chemicals, have surged nearly 51% over the past month amid anti-dumping duties imposed by the US and the European Union (EU) on Chinese manufacturers. ADVERTISEMENT The move is expected to benefit the company's aroma exports business over the next three-four quarters. However, investors should remain cautious, as sustaining such returns will depend on the company's ability to deliver strong financial performance in the medium term. The EU imposed anti-dumping duties of 131.1% on imports of vanillin, an organic compound, originating in China following a similar move by the US last year. These actions have driven up vanillin prices in both regions, which are significant export markets for Camlin. Camlin's business involves manufacturing, marketing, and supply of specialty chemicals used across various industries-including food, animal feed, pet nutrition, fragrance, pharmaceuticals, and industrial products. Its blends and aroma businesses, which include vanillin, were the primary drivers of growth in the previous financial year. The blends segment generated ₹878 crore in revenue in FY25 up from ₹747 crore in the previous financial year while revenue from the aroma ingredients segment surged to ₹176 crore from ₹35 crore in FY24. Total revenue improved by 15% to ₹1,666.5 crore for by the increase in the prices, the company plans to increase its vanillin capacity utilisation from the current 45-50% to 100% over the next two years that would lead to lower cost per unit. ADVERTISEMENT "We should grow blends business by about 20% in the next two to three years and the Ebitda margins will improve in some of the geographies. So it will be in the high teens," Nirmal Momaya, managing director, Camlin Fine Sciences told analysts during an earnings call. The company's Ebitda margin was 12.5% in FY25 compared with 12.6% in the previous company's net debt declined to ₹492 crore as of March 2025 from ₹564 crore a year ago, improving the net debt-to-equity ratio to 0.5 from 0.7. ADVERTISEMENT Higher growth potential and improved debt position has prompted brokerages to raise the company's valuations. "We raise the valuation multiple to 15 times FY27 expected earnings (previously 12 times) to reflect the anticipated improvement in performance due to increasing share of high margin blends, rising vanillin prices, and improving profitability," said Axis Securities in a stock was ended at ₹300 on Wednesday on the BSE, reflecting 182% jump from the year-ago level. (You can now subscribe to our ETMarkets WhatsApp channel)
&w=3840&q=100)
Business Standard
3 days ago
- Business
- Business Standard
2 smallcaps zoom up to 153% from April low. What's driving these stocks?
Share price of Suven Life Sciences, Camlin Fine Sciences today Shares of Suven Life Sciences (Suven) and Camlin Fine Sciences (CFSL) hit their respective new highs, surging up to 9 per cent on the BSE in Monday's intra-day trade. The stock price of both these smallcap companies have outperformed the market, by zooming up to 153 per cent from their April month lows. On April 7, 2025, the market including BSE Sensex, BSE Midcap and BSE Smallcap indices recorded their respective 52-week lows. Individually, Suven has rallied 9 per cent to ₹257.70 in intra-day trade today. In the past one month, the market price of the healthcare research, analytics & technology company has surged 36 per cent. It has bounced back 124 per cent from its April 7, 2025 low of ₹115 on the BSE. Shares of Camlin soared 7 per cent to ₹324.20, surging 67 per cent in the past one month. The stock price of this specialty chemicals makee has zoomed 153 per cent from a level of ₹128.10 touched on April 7, 2025. What's driving Suven, Camlin stock prices? CFLS reported a strong operational performance for the March 2025 quarter (Q4FY25). The company reported 88.7 per cent year-on-year (YoY) growth in earnings before interest, taxes, depreciation and amortisation (EBITDA) from its continuing operations at ₹59.41 crore, as against ₹31.48 crore in Q4FY24. Reported EBITDA margins expanded to 13.6 per cent from 8.4 per cent from the year ago quarter. Revenue from operations grew 16.1 per cent YoY to ₹437.46 crore from ₹376.65 crore. Profit after tax (PAT) increased 16.9 per cent YoY at ₹22.74 crore. At the consolidated level, CFSL derives around 85 per cent of its revenue from exports and from overseas subsidiaries, with over 100 products sold in around 80 countries. The company caters to diverse end user industries such as food, feed, animal and pet nutrition, flavours and fragrances, pharma, agrochemicals, and petrochemicals among others. This helps the company avoid dependence on any single industry and provides potential for expansion. Management anticipates sustained momentum in this segment, projecting a compounded annual growth rate (CAGR) of ~20 per cent over the next 2–3 years. Margins are expected to expand further as the bleeding from continued operations reduces and other operations grow. Camlin is also set to benefit from the implementation of anti-dumping measures in the US and improving Vanillin prices. While steady performance improvement is expected, the analysts remain cautious of near-term uncertainties related to tariffs and capacity ramp-up. Suven, a bio-pharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally. On May 13, the board of directors of Suven approved fund raising of ₹857.64 crore through fully convertible warrants on preferential basis to continue the funding of R&D, Clinical Development programs and general corporate purposes and CAPEX for creating new R&D facilities. Suven has a significant opportunity in the rapidly growing CNS segment. The segment has limited competition due to high associated risks. CNS diseases include a broad spectrum of disorders in which the brain or spinal cord functioning is diminished or impaired, resulting in diminished motor, sensory, or cognitive performance. The rising prevalence of CNS disorders, such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis and depression, drives the demand for effective CNS therapeutics. Furthermore, the pandemic has resulted in increased stress levels, anxiety, depression and other mental conditions. This has led to an increased demand for CNS therapies. Suven continues its R&D programs focused on CNS disease disorders and has secured 20 patents during the period covering countries Brazil, Eurasia, Europe, Hong Kong, India, Israel, Japan, Macao, Mexico, New Zealand, Sri Lanka, South Africa and the US.
India.com
06-06-2025
- Entertainment
- India.com
Aishwarya Rai was set to make her Bollywood debut with Kuch Kuch Hota Hai, Raja Hindustani, rejected it due too.., her first film then flopped, name was…
Before becoming a huge phenomenon and achieving massive stardom, Aishwarya Rai Bachchan made headlines for reasons beyond the silver screen. While many aspiring stars chase any chance to break into Bollywood, she took an unusual path, turning down major film offers even before her official debut. However, she later made her debut with the film that became a box office bomb. When Aishwarya Rejected Blockbusters Before Her Debut Aishwarya Rai Bachchan appeared in front of the camera for the first time while she was in Class IX. She featured in a commercial for Camlin pencils. In 1994, she won Miss India and claimed that she had previously been offered four films, all of which she declined. During an interview with Vogue, the actress mentioned that she was offered films like Raja Hindustani and Kuch Kuch Hota Hai , but she declined them. The actress said, 'I'm often cited as the person who established the beauty pageant-to-films route, but that was not the case with me. I had at least four film offers. I decided to participate in Miss India to step back from the film industry for a bit. If I hadn't taken part in Miss India , Raja Hindustani would have been my first film.' She also stated that she rejected Kuch Kuch Hota because she disliked Tina's character, who had straight hair and wore tiny dresses, and believed that viewers would mock her character in the film. Her debut was established with the 1997 film Aur Pyaar Ho Gaya , alongside Bobby Deol , which became box office disaster. Later on, she gained a large following for her impeccable on-screen talent and capability in films such as Taal, Josh, Jeans, Mohabbatein, Devdas , and many others. More about Aishwarya Rai Bachchan In 2007, Aishwarya tied the knot with Amitabh Bachchan's son, actor Abhishek Bachchan and in 2011 she gave birth to her first child Aaradhya Rai Bachchan . The actress last appeared on the big screen in the Tamil film Ponniyin Selvan: II , which came out in 2023. It was the sequel to the 2022 film Ponniyin Selvan: I , which was helmed by Mani Ratnam .
Time of India
29-04-2025
- Business
- Time of India
Kokuyo to buy office furniture maker HNI India
MUMBAI: Japan's Kokuyo , which entered India by acquiring the Camlin stationery brand in 2012, is set to buy office furniture manufacturer HNI India from NYSE-listed HNI Corporation to expand its presence in the country. HNI India, with a revenue of Rs 250 crore, operates a 3.5 lakh square feet manufacturing facility in Nagpur and employs about 350 people. HNI is selling its India business to streamline its portfolio. It previously sold its Hong Kong and China units to Kokuyo for $75 million in 2022. Once the HNI India acquisition is completed, the Japanese company will market office chairs , modular office furniture, and other workplace solutions under the Kokuyo brand. TNN Stay informed with the latest business news, updates on bank holidays and public holidays . Master Value & Valuation with ET! Learn to invest smartly & decode financials. Limited seats at 33% off – Enroll now!
